From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Avacta now sub 40p: when is the next discounted placing? Stay short, initial target 20p

By Tom Winnifrith | Tuesday 18 February 2025


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


The real problem Avacta (AVCT) is that trials of its lead product, the store of all the hopium in the share price, does not seem to work as Deutsche bank pointed out last Autumn.56 patients took it none were cured. If those results don’t change there is no way that AVA 6000 will make it out of phase 2 trials with Avacta, just as it failed to make it out of phase 2 a decade ago under its previous owner. That is the harsh truth chatroom gerbils have yet to accept.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Sunday »

EZJ

BUY Easyjet

 

PDL

Petra Diamonds Remains a Short

 

Boom

Failed fund manager for PM!

 

Oil-Rig

Oilman Jim: is this legal?

Time left: 08:04:28